



## CompuGroup Medical SE & Co. KGaA

Contact:

**Claudia Thomé**

Senior Vice President IR &  
Interim Head of Corporate Communications

M: +49 160 3630362

E-mail: [claudia.thome@cgm.com](mailto:claudia.thome@cgm.com)

Web: [www.cgm.com](http://www.cgm.com)

*Press release, March 5, 2026*

## CompuGroup Medical maximizes customer benefit with targeted product innovations

- **Revenues in fiscal year 2025 at EUR 1.213 billion (+5 percent vs. previous year)**
- **Growth in all operating segments**
- **Focus on product innovations and customer experience**
- **Dividend proposal of EUR 0.50 per share**
- **Growth expected for 2026**

Koblenz – CompuGroup Medical, one of the world’s leading e-health providers, has set the course for further qualitative growth in fiscal year 2025. The specialist for software solutions in healthcare is driving forward digitization along the entire patient-related value chain through the targeted expansion of cloud, platform, and AI solutions. With a clear focus on product innovation and the introduction of agile, cross-functional teams – from software development via service and support to sales and marketing – the company consistently

CompuGroup Medical SE & Co. KGaA · Maria Trost 21 · 56070 Koblenz · T +49 261 8000-0 · F +49 261 8000-1166 · [www.cgm.com](http://www.cgm.com)  
Chairman of the Supervisory Board: Philipp von Ilberg · Company domiciled in: Koblenz · HRB 27430 · Local Court Koblenz

General Partner: CompuGroup Medical Management SE · Company domiciled in: Koblenz · HRB 27343 · Local Court Koblenz  
Chairman: Frank Gotthardt

Managing Directors: Prof. (apl.) Dr. med. Daniel Gotthardt (CEO), Daniela Hommel, Emanuele Mugnani, Hannes Reichl, Dr. Guido Schroeder  
VAT-ID.: DE114134699 · Commerzbank Koblenz · IBAN: DE60 5704 0044 0208 0026 00 · BIC: COBADEFFXXX



aligns all processes with the requirements of its global customer base, thereby bundling its operational firepower.

CEO Prof. (apl.) Dr. med. Daniel Gotthardt emphasizes: “Our customers are at the heart of all our further developments. We want to make it as easy as possible for healthcare professionals to care for their patients so that they can achieve excellent medical results. That is why we continue to develop our software solutions in close collaboration with experts from the medical field. Our integrated, networked platforms are complemented by our global teams with scalable cloud and hybrid solutions as well as data- and AI-driven services. Our customers can benefit from this throughout the entire care pathway.”

In the **AIS segment**, CGM is consistently developing established Ambulatory Information Systems and expanding them via the cloud-based CGM ONE platform to include AI-supported services such as CGM Praxis, TelefonAssistent, and DokuAssistent. In the dental sector, CGM XDENT offers fully cloud-based practice software specifically for modern solo practices and practice founders. In the **HIS segment**, the company is focusing on expanding the CGM CLINICAL Suite based on open CGM G3 technology. Key elements here are the SAP IS-H successor solution CGM CLINICAL RCM and AI innovations such as the dialog-oriented CGM HIS Assistant, which significantly simplifies clinical documentation and workflows. In the **PCS segment**, CGM is driving forward the digitization of pharmacies with its cloud-based pharmacy software CGM STELLA, reducing their workload with secure cloud infrastructures and intelligent, practical workflows. Overall, CGM combines modern cloud technology, Artificial Intelligence, and modular platforms to enable medical practices, hospitals, and pharmacies to measurably improve their processes and gain more time to care for their patients.

In fiscal year 2025, the Group generated annual revenues of EUR 1.213 billion (2024: EUR 1.154 billion). This represents an increase of 5 percent over the previous year. Organic



revenues also grew by 5 percent, following a 3 percent decline in revenues in the previous year. Thus, the guidance for revenue growth was achieved at the upper end of the expected range. Recurring revenues rose by 3 percent. The development of EBITDA (EUR 195 million, down by 11 percent year-on-year) primarily reflects increased expenses for research and development, increasing customer centricity, and one-time transaction expenses. A dividend of EUR 0.50 per eligible share is proposed for the 2025 financial year (2024: EUR 0.05), subject to approval by the Annual General Meeting scheduled for April 17, 2026. The number of employees remained roughly at the previous year's level at just over 8,700.

For fiscal year 2026, CompuGroup Medical expects organic growth in total Group revenues (adjusted for acquisitions and currency effects) in the low to mid-single-digit percentage range and a slight increase in the cash EBITDA margin. Slight organic revenue growth is expected for all three reporting segments. In the upcoming years, CGM plans to further strengthen the Group's position as one of the leading international providers of IT solutions for the healthcare sector and to benefit from the increasing use of Artificial Intelligence in the long term.

The complete 2025 annual report is available on the CompuGroup Medical website at [www.cgm.com/ir-publications](http://www.cgm.com/ir-publications).

### **About CompuGroup Medical SE & Co. KGaA**

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.21 billion in 2025, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories, hospitals and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. The basis of CompuGroup Medical's services is its unique customer base, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities, as well as insurance and pharmaceutical companies. CompuGroup Medical has offices in 19 countries and offers its solutions in 60 countries

CompuGroup Medical SE & Co. KGaA · Maria Trost 21 · 56070 Koblenz · T +49 261 8000-0 · F +49 261 8000-1166 · [www.cgm.com](http://www.cgm.com)  
Chairman of the Supervisory Board: Philipp von Ilberg · Company domiciled in: Koblenz · HRB 27430 · Local Court Koblenz

General Partner: CompuGroup Medical Management SE · Company domiciled in: Koblenz · HRB 27343 · Local Court Koblenz  
Chairman: Frank Gotthardt

Managing Directors: Prof. (apl.) Dr. med. Daniel Gotthardt (CEO), Daniela Hommel, Emanuele Mugnani, Hannes Reichl, Dr. Guido Schroeder  
VAT-ID.: DE114134699 · Commerzbank Koblenz · IBAN: DE60 5704 0044 0208 0026 00 · BIC: COBADEFFXXX



worldwide. More than 8,700 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

CompuGroup Medical SE & Co. KGaA · Maria Trost 21 · 56070 Koblenz · T +49 261 8000-0 · F +49 261 8000-1166 · [www.cgm.com](http://www.cgm.com)  
Chairman of the Supervisory Board: Philipp von Ilberg · Company domiciled in: Koblenz · HRB 27430 · Local Court Koblenz

General Partner: CompuGroup Medical Management SE · Company domiciled in: Koblenz · HRB 27343 · Local Court Koblenz  
Chairman: Frank Gotthardt

Managing Directors: Prof. (apl.) Dr. med. Daniel Gotthardt (CEO), Daniela Hommel, Emanuele Mugnani, Hannes Reichl, Dr. Guido Schroeder  
VAT-ID.: DE114134699 · Commerzbank Koblenz · IBAN: DE60 5704 0044 0208 0026 00 · BIC: COBADEFFXXX